Perceptions, Experiences, and Patterns of Cannabis Use in Individuals with Mood and Anxiety Disorders in the Context of Cannabis Legalization and Medical Cannabis Program in Canada – A Qualitative Study
Ankita Das, Christian S. Hendershot, Muhammad Ishrat Husain, Yuliya Knyahnytska, Sonja Elsaid, Bernard Le Foll, Stefan Kloiber
Pharmacopsychiatry March 11, 2024 DOI: 10.1055/a-2264-1047 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Qualitative study Peer reviewed |
|---|---|
| Sample size | 36 |
| Population | Adults diagnosed with mood or anxiety disorders, obsessive-compulsive disorder, or posttraumatic stress disorder who were currently using cannabis |
| Topics | Anxiety Cannabis |
| Citations | 15 |
| Key findings | Participants reported starting cannabis out of curiosity, peer pressure, and dissatisfaction with conventional treatments, and continuing for psychotropic effects and to cope with mental health symptoms and insomnia. With ongoing use they acknowledged more negative effects, including cognitive dysfunction and worsening mood and anxiety. The authors highlight common initiation before age 18, combined medical and recreational use, and rare consultation with medical professionals as concerns. |
Abstract
Introduction: Perceptions of cannabis as a potential medical treatment for mood and anxiety disorders have been increasing in the context of legalizations, availability, and medical cannabis programs, though current evidence predominately indicates risks and negative effects of cannabis use (CU) on mental health outcomes. This study aims to understand motivations, perceptions, effects, and patterns of CU in individuals with mood and anxiety disorders.
Methods: Thirty-six adult patients diagnosed with mood or anxiety disorders, obsessive-compulsive disorder, or posttraumatic stress disorder who were currently using cannabis completed an in-depth qualitative interview on individual motivations, perceptions, experiences, effects, and patterns of their CU. The thematic analysis focused on phases of CU and sources of cannabis products and information.
Results: Reported motivations for initiation of CU included curiosity, peer pressure, and dissatisfaction with conventional treatments. Factors such as psychotropic effects and coping with mental health symptoms and insomnia contributed to the continuation of CU. More negative effects, including cognitive dysfunction, worsening of mood, and anxiety symptoms, were acknowledged with ongoing CU. Concerning findings included common initiation of CU before age 18, combined medical and recreational CU, rare consultation of medical professionals on CU, and potential effects and harms.
Discussion: Findings indicate individual complexity of motivations, perceptions, and patterns of CU in the study population. The reported potential beneficial effects of specific cannabis products should be further investigated. Findings emphasize patient-provider dialogue on both CU and conventional treatments. Information from this study can contribute to and inform the development of education, prevention, and intervention strategies.
Comparable studies
Other qualitative studies on cannabis for anxiety, most cited first.
Citations in the library
Cites 5
- Cannabis use before age 15 and subsequent executive functioning The British Journal of Psychiatry May 31, 2011
- A naturalistic examination of the perceived effects of cannabis on negative affect. Journal of Affective Disorders August 1, 2018
- Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults: A Systematic Review and Meta-analysis JAMA Psychiatry June 1, 2018
- Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being Psychological Medicine February 1, 2012
- Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Research August 2011